Georgios Pongas, MD
Hematology & Oncology · Miami, FLNPI 1487974770
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,050 of the $15,645 with a category attached, or 83.4%. ADC Therapeutics America, Inc. accounts for 68.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $10,961 and has fallen 76.4% since, to $2,583 in 2025.
Across 42 payments — averaging $372.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$11K
- Beigene USA, Inc.$3K
- AstraZeneca$547
- Beigene, Ltd.$450
- Beone Medicines USA, Inc.$267
- Genentech, Inc.$181
- plus $746 from 11 others
Across 16 payments — averaging $12,209 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beone Medicines USA, Inc.$105K
- Beigene USA, Inc.$43K
- F. Hoffmann-la Roche AG$25K
- Beone Medicines Ltd.$23K
What the payments were for
- Consulting fees$13,05083%
- Travel & lodging$9136%
- Food & beverage$1,68211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 9 | $10,692 |
| Beigene USA, Inc. | 6 | $2,763 |
| AstraZeneca | 2 | $547 |
| Beigene, Ltd. | 1 | $450 |
| Beone Medicines USA, Inc. | 2 | $267 |
| Genentech, Inc. | 2 | $181 |
| Acrotech Biopharma Inc. | 1 | $130 |
| Johnson & Johnson | 4 | $127 |
| Kyowa Kirin, Inc. | 2 | $115 |
| Seagen Inc. | 3 | $102 |
| Genmab U.S., Inc. | 1 | $93 |
| Genentech USA, Inc. | 3 | $61 |
| Novartis | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Sanofi | 1 | $22 |
| Pfizer | 1 | $17 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,645 in reported general payments places this provider in the 70th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 52 | $644,688 |
| BrukinsaZanubrutinib | 22 | $315,100 |
| CalquenceAcalabrutinib Maleate | 19 | $282,040 |
| ImbruvicaIbrutinib | 18 | $266,286 |
| Bexarotene | 29 | $242,648 |
| Entecavir | 12 | $5,194 |
| Acyclovir | 98 | $866 |
| Allopurinol | 19 | $80 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $72 |
| Prednisone | 15 | $56 |
| Levofloxacin | 13 | $37 |
| Levothyroxine Sodium | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $2,763 | $315,10022 claims |
| AstraZenecaCalquence | $547 | $282,04019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.